Treatment guidelines for type 2 diabetes (T2D) recommend a comprehensive, individualised approach with multiple therapeutic goals (including HbA1c reduction and body weight loss), as many people with T2D are associated with several comorbid conditions.

Composite endpoints provide physicians with a holistic view of the clinical benefit of treatments, and a foundation for clinical decision-making.

This post hoc analysis of the PIONEER 1–5 and 8 trials evaluated composite endpoints of ≥ 1% reduction in HbA1c and plus either a ≥ 5% or ≥ 10% reduction in body weight with orally administered semaglutide versus comparators in people with T2D.

The odds of achieving clinically relevant reductions in both HbA1c and body weight were significantly greater with orally administered semaglutide versus comparators.